SOR102 is a novel oral bispecific antibody targeting both Tumor Necrosis Factor (TNF) and Interleukin-23 (IL-23) p19.
The Phase 1 trial demonstrated that SOR102 is well-tolerated in both healthy volunteers and patients with mildly-to-severely active ulcerative colitis.
Preliminary efficacy data in Part 3 showed a 56% clinical response rate in the twice-daily SOR102 group compared to 17% in the placebo group by day 42.
Oral delivery of SOR102 offers the potential for high local gut concentrations with minimal systemic exposure, potentially reducing systemic side effects common in parenteral biologics.
The Challenge of Refractory Ulcerative Colitis
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
